Newsflash: The Dividend Aristocrats Found The Lost Decade
There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions.
Read more »|
Price
$24.70
|
Market Cap
2.07B
|
Sector
Health Care
|
Div. Growth
-
|
|
P/E
47.2
|
P/B
5.01
|
P/S
5.31
|
Dividend %
-
|
|
P/CF
-
|
P/FCF
70.8
|
Op. Cash Flow
54.4
|
FCF/Share
0.3
|
|
Op. Margin
20.80%
|
Net Margin
11.60%
|
ROE
11.80%
|
ROI
6.40%
|
|
ROA
7.10%
|
EPS Growth
3.90%
|
Curr. Ratio
3.8
|
Debt/Equity
85.0
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| CAS Medical Systems Inc (CASM) | $1.95 | - | - | 34.3M | |
| DGT Holdings corp (DGTC) | $9.00 | - | - | 35.5M | |
| Rosetta Genomics Ltd. (USA) (ROSG) | $6.86 | - | - | 3.2M | |
| TLC Vision Corporation (USA) (TLCV) | $0.01 | - | - | 300K | |
| Remedent, Inc. (REMI) | $0.28 | - | - | 7M |
There are many people who continue to hold a jaundiced view of stocks because they were traumatized by the last two recessions.
Read more »I'm inspired to write this article because I am so frustrated by the plethora of all the so-called expert market prognosticators that continuously bombard the public with negative forecasts.
Read more »One of the great long-term benefits that a recession brings is the opportunity to invest in extremely high-quality companies at low valuations.
Read more »Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
All articles will be reviewed prior to publishing. You will be notified by email if we choose to publish your article.
×